Lab Tests Diagnostic Medical Tests Medical Lab Tests
 Red blood cell count
 Red cell indices
 sedimentation rate
 Reticulocyte count
 Osmotic fragility
 Total hemoglobin
 Fetal hemoglobin
 Sickle cell test
 Unstable hemoglobin
 Heinz bodies
   Iron and total
 iron-binding capacity
 White blood cell count
   White blood cell
 Bleeding time
 Platelet count
 Capillary fragility
 Platelet aggregation
   Activated partial
 thromboplastin time
 Prothrombin time
 Activated clotting time
   One-stage factor
 coagulation system
   One-stage factor
 coagulation system
 Plasma thrombin time
 Plasma fibrinogen
 Fibrin split products
 Plasma plasminogen
 Protein C
 Euglobulin lysis time
 normalized ratio

Home :: Fibrin split products

Fibrin Split Products

After a fibrin clot forms in response to vascular injury, the clot is eventually degraded by plasmin, a fibrin-dissolving enzyme. The resulting fragments arc known as fibrin split products (FSP), or fibrinogen degradation products. In this test, FSP are detected in the diluted serum that is left in a blood sample after clotting.


  • To detect FSP in the circulation
  • To help determine the presence and the approximate severity of a hyperfibrinolytic state (such as disseminated intravascular coagulation [DIC]) that may result in primary fibrinogenolysis or hypercoagulability.

Patient preparation

  • Explain to the patient that this test is used to determine if blood clots normally.
  • Tell him that a blood sample will be taken Explain who will perform the venipuncture and when.
  • Reassure him that drawing a blood sample will take less than 3 minutes.
  • Explain that he may feel slight discomfort from the tourniquet pressure and the needle puncture.
  • Check patient history for use of any medications (especially heparin) that may interfere with accurate determination of test results.
  • Inform the patient that food or fluids not be restricted before the test.

Procedure and posttest care

  • Perform a venipuncture, and then draw 2 ml of blood into a plastic syringe.
  • Transfer the sample to the tube provided by the laboratory, which contains soybean trypsin inhibitor and bovine thrombin.
  • If a hematoma develops at the veniclnre site, apply warm soaks
  • Draw the sample before administering heparin to avoid false-positive test results.
  • Gently invert the collection tube several times to mix the contents thoroughly.
  • The blood clots within 2 seconds and then must be sent immediately to the laboratory, to be incubated at 98.60 F (370 C) for 30 minutes before testing proceeds.

Reference values

Serum contains less than 10 ug/ml of FSP. A quantitative assay shows levels of less than 3 ug/ml.

Abnormal findings

FSP levels increase in primary fibrinolytic states, due to increased levels of circulating profibrinolysin; in secondary states, due to DIC and subsequent fibrinolysis; and in alcoholic cirrhosis, preeclampsia, abruptio placentae, congenital heart disease, sunstroke, bums, intrauterine death, pulmonary embolus, deep-vein thrombosis (transient increase), and myocardial infarction (after 1 or 2 days). FSP levels usually exceed 100ug/ml in active renal disease or renal transplant rejection.

Interfering factors

  • Pretest administration of heparin (false-high).
  • Failure to fill the collection tube completely, to adequately mix the sample and additive, or to send the sample to the laboratory immediately.
  • Hemolysis due to rough handling of the sample.
  • Fibrinolytic drugs, such as urokinase and streptokinase, and large doses of barbiturates (increase).

Diagnostic Medical Tests
Medical Tests
Dagnostic Tests
Lab Tests

Contact us | Link to us | Lab tests
Resources - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
(c)Copyright All rights reserved.

The information provided on this web site should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. We will not be liable for any complications, or other medical accidents arising from the use of any information on this web site.